Roth David 4
4 · Syros Pharmaceuticals, Inc. · Filed Apr 5, 2024
Insider Transaction Report
Form 4
Roth David
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-04-03$4.95/sh−10,451$51,732→ 0 total
Footnotes (1)
- [F1]The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.